Remibrutinib reduced the need for rescue medication and improved symptoms among patients with chronic spontaneous urticaria, according to a study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress.
Also, remibrutinib (LOU064, Novartis) achieved these outcomes despite reduced use of second-generation H1 antihistamines (H1-AH), Marcus Maurer, MD, professor of dermatology and allergy and associate director of the Allergie-Centrum-Charité in Berlin, said in his presentation.
“Now we have another treatment option here, which I find very promising,”